IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Q4 2019 IRadimed Corp Earnings Call
WINTER SPRINGS, Fla., March 06, 2020 -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that Leslie McDonnell, President and Chief Executive Officer, will present at the.
Earlier, IRadimed released financial results for first-quarter 2020. The agenda for today's call will be as follows: Leslie McDonnell, president and chief executive officer of IRadimed, will present opening comments; then Chris Scott, IRadimed's chief financial officer, will summarize the company's financial results before opening the call up to questions. Forward-looking statements are those focused on the future performance results, plans and events and may include the company's expected results for 2020.
iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Q1 2020 IRadimed Corp Earnings Call
IRADIMED CORPORATION (IRMD) announced the retirement of Francis Casey, Vice President of Regulatory Affairs and Quality Assurance, effective June 30, 2020 after leading the Company’s regulatory efforts since 2004. IRADIMED appointed Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance, succeeding Mr. Casey, effective March 10, 2020. Mr. Kachelmeyer will report to Leslie McDonnell, President and Chief Executive Officer.
IRADIMED CORPORATION (IRMD) announced that it expects to report first quarter 2020 revenue of $8.6 million to $8.7 million and is withdrawing its first quarter and full year 2020 financial guidance due to the uncertainty created by COVID-19. As the focus of our customers has turned toward caring for those infected with the virus, we saw an accelerating decline in equipment orders throughout March.
WINTER SPRINGS, Fla., April 16, 2020 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 first quarter financial results before.
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WINTER SPRINGS, Fla., May 11, 2020 -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced the issuance by the U.S. Patent and Trademark Office of a patent that expands on.
IRADIMED CORPORATION (IRMD) announced the appointment of Lynn Neuhardt as Vice President of Research and Development, effective March 26, 2020. Mr. Neuhardt will report to Leslie McDonnell, President and Chief Executive Officer. Lynn will lead our talented R&D team and collaborate closely with Roger Susi, our founder and Chief Technology Officer.
To the annoyance of some shareholders, IRadimed (NASDAQ:IRMD) shares are down a considerable 42% in the last month...
Reports fourth quarter 2019 revenue of $10.9 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.30Renewed CE Mark for patient vital signs monitor and shipped.
WINTER SPRINGS, Fla., Jan. 22, 2020 -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2019 fourth quarter financial results before.
Shares of iRadimed (NASDAQ:IRMD) rose 0.2% after the company reported Q1 results.Quarterly Results Earnings per share were up 38.46% year over year to $0.18, which beat the estimate of $0.15.Revenue of $8,678,000 up by 2.84% from the same period last year, which missed the estimate of $9,660,000.Guidance iRadimed hasn't issued any earnings guidance for the time being.iRadimed hasn't issued any revenue guidance for the time being.Details Of The Call Date: Apr 30, 2020View more earnings on IRMDTime: 12:01 PM ETWebcast URL: https://edge.media-server.com/mmc/p/tcmonbtyPrice Action Company's 52-week high was at $29.74Company's 52-week low was at $14.41Price action over last quarter: down 18.00%Company Overview iRadimed Corp is a US-based company that mainly develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.See more from Benzinga * Recap: Silicom Q1 Earnings * Proto Labs: Q1 Earnings Insights * Recap: Hilton Grand Vacations Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Reports first quarter 2020 revenue of $8.7 million, GAAP diluted EPS of $0.14 and non-GAAP diluted EPS of $0.18Reports combined cash and investments of $47.4 million as of March.
Even with high percentages in cash, Nintai portfolios held their own against the major indexes Continue reading...